Evidence map›Paper›PMID 41097660›Full record

ArticleCancers2025

Impact of Epigenome-Wide Methylation and Breast Cancer Recurrence in Women Tested Negative for BRCA Genes: The Breast Methylation Risk (BREMERI) Study.

Silvia Polidoro, Harriet Johansson, Giovanni Cugliari, Aliana Guerrieri-Gonzaga, Valentina Aristarco, Debora Macis, Mariarosaria Calvello, Monica Marabelli, Irene Feroce, Davide Serrano and 6 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Silvia PolidoroDepartment of Translational Medicine, University of Piemonte Orientale, 28100 Novara, Italy.ORCID 0000-0003-2968-0575
Harriet JohanssonDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0002-4131-2030
Giovanni CugliariDepartment of Medical Sciences, University of Turin, 10124 Turin, Italy.ORCID 0000-0002-6080-0718
Aliana Guerrieri-GonzagaDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0003-1915-1688
Valentina AristarcoDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0002-4939-6240
Debora MacisDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0002-0633-2933
Mariarosaria CalvelloDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0003-2113-8503
Monica MarabelliDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.
Irene FeroceDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0001-9312-2020
Davide SerranoDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0002-2945-4108
Sara CagnacciDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0003-1721-8332
Cristina ZanzotteraDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0001-5691-722X
Francesca FavaDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0002-4363-2353
Federica BellerbaDepartment of Experimental Oncology, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0002-5956-4340
Bernardo BonanniDivision of Cancer Prevention and Genetics, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0003-3589-2128
Sara GandiniDepartment of Experimental Oncology, European Institute of Oncology, IEO, IRRCCS, 20141 Milan, Italy.ORCID 0000-0002-1348-4548

Funding

Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Monzino (FIEO-CCM) Not available
6 · The paper itself

Abstract

BACKGROUND AND

aimDNA methylation may contribute to a worsening in breast cancer (BC).

methodsWe conducted a matched case-control study to investigate the contribution of DNA methylation (DNAm) in breast cancer recurrence risk. Genome-wide DNAm profiles were generated from peripheral white blood cells (WBC) collected post-surgery from women with primary breast cancer

resultsWe identified three differentially methylated regions between the groups. Cases showed two hypomethylated regions, one upstream of the

conclusionsOur exploratory study suggests that specific DNA methylation patterns in WBCs, particularly in genes related to cellular proliferation, invasion, and glucose homeostasis, may be associated with the risk of breast cancer recurrence in

Indexed as

breast cancerDNA methylationepigeneticsglucose homeostasis

Identifiers

PMID41097660
PMCPMC12524240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.